Tritanrix HB

Tritanrix HB Uses, Dosage, Side Effects, Food Interaction and all others data.

1 dose (0.5 ml) contains:

Diphtheria toxoid: Not less than 30 IUTetanus toxoid: Not less than 60 IUBordetella pertussis (inactivated): Not less than 4 IUHepatitis B surface antigen: 10 microgramsVaccine is used for the active immunisation of diphtheria, tetanus and pertussis in children from 6 wk to 6 yr of age. Production of specific antibodies to tetanus, diphtheria, and pertusis (active immunity). Conveys active immunity via stimulation of production of endogenously produced antibodies

This vaccine contains diphtheria (D), tetanus (T) toxoids, inactivated pertussis bacteria (Pw) and the purified major surface antigen of the hepatitis B virus (HBV), adsorbed on aluminium salts.

The D and T toxoids are prepared from the toxins of cultures of Corynebacterium diphtheriae and Clostridium tetani by formalin inactivation using established technology. The Pw component is obtained by heat inactivation of phase I culture of Bordetella pertussis bacteria.

The surface antigen of the HBV (HBsAg) is produced by culture of genetically-engineered yeast cells (Saccharomyces cerevisiae) which carry the gene coding for the major surface antigen of the HBV. This HBsAg expressed in yeast cells is purified by several physico-chemical steps. The HBsAg assembles spontaneously, in the absence of chemical treatment, into spherical particles of 20 nm in average diameter containing non-glycosylated HBsAg polypeptide and a lipid matrix consisting mainly of phospholipids. Extensive tests have demonstrated that these particles display the characteristic properties of the natural HBsAg.

Tritanrix HB
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Tritanrix HB
Generic	Diphtheria Toxoid + Tetanus Toxoid + Bordetella Pertussis + Hepatitis B (Vaccine)
Weight	(30iu+60iu+4iu+10mcg)/0.5ml
Type	Injection
Therapeutic Class	Vaccines, Anti-sera & Immunoglobulin
Manufacturer	GlaxoSmithKline
Available Country	Bangladesh
Last Updated:	September 19, 2023 at 7:00 am

Uses

This vaccine is used for active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards

Dosage

Tritanrix HB dosage

Primary vaccination: The primary vaccination schedule consists of three doses within the first six months of life. Where HBV vaccine is not given at birth, the combined vaccine can be administered beginning as early as 8 weeks of age. Where there is a high endemicity of HBV, the practice to administer HBV vaccine at birth should be continued. In these circumstances, vaccination with the combined vaccine should start at 6 weeks of age.

Three vaccine doses must be administered at intervals of at least 4 weeks.

When this vaccine is given according to the 6-10-14 weeks schedule, it is recommended to administer a dose of HBV vaccine at birth to improve protection. In the case of children born of known HBV carrier mothers the immunoprophylactic measures for hepatitis B should not be modified. This may require separate vaccination with HBV and DTPw vaccines and also include the administration of HBIg at birth.

Booster vaccination: A booster dose with this vaccine will give rise to increased reactogenicity as would be expected for a booster during the second year of life. In consequence, boostering should follow local recommendations.

The administration of a booster dose with trivalent DTP vaccine is recommended before the end of the second year of life. For long-term protection against HBV, a booster dose of HBV vaccine could also be administered after the first year of life. However, the need for this dose is currently not established.

HIV infected patients:Individuals infected with the human immuno-deficiency virus (HIV), both asymptomatic and symptomatic, should be immunized with this vaccine according to standard schedules

Tritanrix HB is for deep intramuscular injection, preferably in the anterolateral thigh. It is recommended that in patients with thrombocytopenia or bleeding disorders the vaccine be administered subcutaneously

Side Effects

Irritability/ fussiness, Drowsiness, Fever, Loss of appetite, Swelling, Fever, Anorexia,Apnea, Erythema, Decreased, consciousness, Diarrhea, Hypotonia, Encephalitis, Brachial neuritis, Erythema, Peripheral neuropathy, Cough, Lethargy, Limb pain, Liver function test abnormalities, Rash, Restlessness

Precaution

Previous reaction to DTP vaccine; family history of convulsions, SIDS; bleeding dis-orders; immunosuppression /deficiency; pregnancy, lactation. Postpone vaccination in patients with acute severe febrile illness. Should be administered SC in patients with thrombocytopenia or bleeding disorders. Syncope, risk of apnea. Temp >40°C, persistent crying lasting >3 hr & collapse or shock-like state with in 48 hrs; convulsions with or withoout fever with in 3 days. High incidence of pertussis. Childn with progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Consider potential risk of apnea & need for resp monitoring for 48-72 hr to very premature infants (>28 wk of gestation) particularly those with previous history of resp immaturity.

Lactation: Not indicated for women of childbearing age

Interaction

There are no known drug interactions and none well documented.

Pregnancy & Breastfeeding use

As this vaccine is not intended for use in adults, information on the safety of the vaccine when used during pregnancy or lactation is not available.

Contraindication

Previous encephalopathy after pertussis vaccine; acute severe febrie illness. Hypersensitivity to any component of the vaccine. Children with history of encephalopathy of unknown etiology occurring within 7 days following previous vaccination. Do not administer IV.